Affordable Access

Access to the full text

Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody

Authors
  • Xiang, Yuhong
  • Parng, Chuenlei
  • Olson, Katrina
  • Seletskaia, Elena
  • Gorovits, Boris
  • Jani, Darshana
  • Caiazzo, Teresa
  • Joyce, Alison
  • Donley, Jean
Type
Published Article
Journal
The AAPS Journal
Publisher
American Association of Pharmaceutical Scientists
Publication Date
Mar 29, 2019
Volume
21
Issue
3
Identifiers
DOI: 10.1208/s12248-019-0320-3
Source
Springer Nature
Keywords
License
Yellow

Abstract

Immunogenicity is a major challenge for protein therapeutics which can potentially reduce drug efficacy and safety and is often being monitored by anti-drug antibody (ADA) and neutralizing antibody (NAb) assays. Circulating targets and residual drugs in matrices can have significant impacts on accuracy of results from ADA and NAb assays, and sufficient drug and target tolerance for these assays are necessary. Here, we report the development of a competitive ligand binding (CLB) NAb assay for an anti-TFPI (tissue factor pathway inhibitor) monoclonal antibody (PF-06741086) with high drug and target tolerance to support ongoing clinical studies. A double acid affinity capture elution approach was used to mitigate drug interference, and a robust target removal strategy was employed to enhance target tolerance. The validated NAb assay has sensitivity of 313 ng/mL, drug tolerance of 50 μg/mL, and target tolerance of 1200 ng/mL. A step-by-step tutorial of assay development is described in this manuscript along with the rationale for using a high drug/target tolerant NAb assay. The NAb assay cut point factor obtained was 0.78. Other assay performance characteristics, e.g., precision and selectivity, are also discussed. This validated method demonstrated a superior drug and target tolerance to warrant specific and precise characterization of the NAb responses in support of ongoing clinical studies.

Report this publication

Statistics

Seen <100 times